| 2022-11-11 |
财报披露：
美东时间 2022-11-11 盘前发布财报
|
| 2022-11-10 |
详情>>
股本变动：
变动后总股本2913.77万股
变动原因 ▼▲
- 原因：
- From June 30, 2022 to September 30, 2022
Common shares issued
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.11美元,归母净利润-3114万美元,同比去年增长40.36%
|
| 2022-09-29 |
股东大会：
将于2022-11-08召开股东大会
会议内容 ▼▲
- 1.To elect each of Gary S. Balkema, Kirk Calhoun, Robert Casale, John W. Hadden II, Michael J. Valentino and Natasha Giordano, to serve as directors until the Company’s 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualify;
2.To consider an advisory vote on the compensation of our named executive officers as disclosed in the proxy statement;
3.To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-08-12 |
详情>>
业绩披露：
2022年中报每股收益-0.82美元,归母净利润-2264.3万美元,同比去年增长25.93%
|
| 2022-05-13 |
详情>>
业绩披露：
2022年一季报每股收益-0.39美元,归母净利润-1078.5万美元,同比去年增长9.09%
|
| 2022-03-11 |
详情>>
业绩披露：
2021年年报每股收益-2.06美元,归母净利润-4865万美元,同比去年增长-187.06%
|
| 2021-11-12 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-2.34美元,归母净利润-5221.23万美元,同比去年增长-517.4%
|
| 2021-10-05 |
股东大会：
将于2021-11-09召开股东大会
会议内容 ▼▲
- 1.to elect each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano, to serve as directors until the Company’s 2022 Annual Meeting of Stockholders and until their successors are duly elected and qualify;
2.to approve an amendment to the PLx Pharma Inc. 2018 Incentive Plan, as amended (the “Plan”), to increase the number of shares of the Company’s common stock issuable under the Plan by 4,000,000 shares;
3.to consider an advisory vote on the compensation of our named executive officers as disclosed in the proxy statement;
4.to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
5.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-06 |
详情>>
业绩披露：
2021年中报每股收益-1.53美元,归母净利润-3056.98万美元,同比去年增长-532.85%
|
| 2021-05-14 |
详情>>
业绩披露：
2021年一季报每股收益-0.73美元,归母净利润-1186.28万美元,同比去年增长-1108.91%
|
| 2021-03-12 |
详情>>
业绩披露：
2020年年报每股收益-1.74美元,归母净利润-1694.8万美元,同比去年增长50.52%
|
| 2021-03-01 |
复牌提示：
2021-03-01 09:36:46 停牌，复牌日期 2021-03-01 09:41:46
|
| 2020-11-13 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.92美元,归母净利润-845.68万美元,同比去年增长73.52%
|
| 2020-09-25 |
股东大会：
将于2020-11-10召开股东大会
会议内容 ▼▲
- 1.to elect each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano, to serve as directors until the Company’s 2021 Annual Meeting of Stockholders and until their successors are duly elected and qualify;
2.to approve an amendment to the PLx Pharma Inc. 2018 Incentive Plan (the “Plan”), to increase the number of shares of the Company’s common stock issuable under the Plan by 1,750,000 shares;
3.to consider an advisory vote on the compensation of our named executive officers as disclosed in the proxy statement;
4.to consider an advisory vote on the frequency of the advisory vote on the compensation of our named executive officers;
5.to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
6.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-08-14 |
详情>>
业绩披露：
2020年中报每股收益-0.53美元,归母净利润-483.05万美元,同比去年增长85.51%
|
| 2020-04-07 |
股东大会：
将于2020-05-15召开股东大会
会议内容 ▼▲
- 1.approve the issuance of more than 20% of our common stock pursuant to a private placement transaction with certain accredited investors and a change of control for purposes of Nasdaq Listing Rule 5635;
2.transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2019-07-02 |
股东大会：
将于2019-08-15召开股东大会
会议内容 ▼▲
- 1.to elect each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano, to serve as directors until the Company’s 2020 Annual Meeting of Stockholders and until their successors are duly elected and qualify;
2.to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-05-20 |
详情>>
内部人交易：
Valentino Michael J股份增加44404.00股
|
| 2019-02-14 |
股东大会：
将于2019-02-19召开股东大会
会议内容 ▼▲
- 1.approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to authorize 1,000,000 shares of “blank check” preferred stock;
2.approve the issuance of more than 20% of our common stock pursuant to a private placement transaction with certain accredited investors and a change of control for purposes of Nasdaq Listing Rule 5635;
3.transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2019-01-10 |
股东大会：
将于2019-02-14召开股东大会
会议内容 ▼▲
- 1.approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to authorize 1,000,000 shares of “blank check” preferred stock;
2.approve the issuance of more than 20% of our common stock pursuant to a private placement transaction with certain accredited investors and a change of control for purposes of Nasdaq Listing Rule 5635;
3.transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2018-08-10 |
股东大会：
将于2018-09-13召开股东大会
会议内容 ▼▲
- 1.to elect each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano, to serve as directors until the Company’s 2019 Annual Meeting of Stockholders and until their successors are duly elected and qualify;
2.to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to approve the Company’s 2018 Incentive Plan;
4.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-20 |
详情>>
拆分方案：
每8.0000合并分成1.0000股
|
| 2016-04-04 |
股东大会：
将于2016-05-24召开股东大会
会议内容 ▼▲
- 1. To elect Robert J. DeLuccia, David P. Luci, Jack H. Dean, Michael Duffy, Thomas Harrison, William J. McSherry, Jr. and Barry Kagan as directors to serve for a term that expires at the 2016 Annual Meeting of Stockholders, or until his successor is elected and qualified or until his earlier resignation or removal;
2. To approve and ratify the Company's Second Amended and Restated Bylaws to add a new section 11.4 to provide that, unless the Company consents in writing to the selection of an alternative forum, a state or federal court located in the State of Delaware shall be the sole and exclusive forum for the following types of litigation: (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer or other employee of the Company to the Company or the Company's stockholders; (iii) any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the Delaware General Corporation Law or the Company's Certificate of Incorporation or the Second Amended and Restated Bylaws (in each case, as they may be amended from time to time); or (iv) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine;
3. To approve an amendment to the Company's Certificate of Incorporation to add a new section to provide that the board of directors is expressly authorized to make, alter, amend or repeal the bylaws of the Company;
4. To ratify the selection of CohnReznick LLP, an independent registered public accounting firm, as the independent auditor of Dipexium Pharmaceuticals, Inc. for the fiscal year ending December 31, 2016;
5. To consider and act upon any other business as may properly come before the annual meeting or any adjournments thereof.
|
| 2015-04-01 |
股东大会：
将于2015-05-15召开股东大会
会议内容 ▼▲
- 1.To elect Robert J. DeLuccia, David P. Luci, Jack H. Dean, Michael Duffy, Thomas Harrison, William J. McSherry, Jr. and Barry Kagan as directors to serve for a term that expires at the 2016 Annual Meeting of Stockholders, or until his successor is elected and qualified or until his earlier resignation or removal;
2.To approve an amendment to the Dipexium Pharmaceuticals, Inc. 2013 Equity Incentive Plan, to increase the shares of our common stock available for issuance thereunder by 433,594 shares from 1,707,575 to 2,141,169;
3.To hold an advisory vote to approve the compensation of the named executive officers;
4.To hold an advisory vote to determine the frequency of future advisory votes on the compensation of the named executive officers;
5.To ratify the selection of CohnReznick LLP, an independent registered public accounting firm, as the independent auditor of Dipexium Pharmaceuticals, Inc. for the fiscal year ending December 31, 2015;
|